한글목차

Kowa Pharmaceuticals가 개발중인 K-321(Ripasudil)은 기존 방수 유출을 증가시키는 것으로 안압을 저하시키는 Rho-키나아제 저해제입니다. Rho-관련 단백질 키나아제(ROCK)는 안구를 포함한 몇개의 조직에서 세포 형태나 동향을 제어하는 단백질입니다.

ROCK 저해제는 기존 유출 조직인 TM(Trabecular Meshwork)과 SC(Schlemm's canal)의 세포내 액틴을 해중합시키는 것에 의해 안압을 저하시킵니다. 또한 ROCK 저해제는 TM세포에 의한 세포외 매트릭스 생산을 억제하므로 안압 하강의 대체약이 될 가능성이 있습니다.

주요 7개국의 K-321 시장에 대해 조사했으며, 시장의 개요와 2025-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 FECD에 대한 K-321의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 K-321 시장 평가

• FECD에 대한 K-321의 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국에서 FECD에 대한 K-321의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"K-321 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about K-321 for Fuchs Endothelial Corneal Dystrophy (FECD) in the seven major markets. A detailed picture of the K-321 for FECD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the K-321 for FECD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the K-321 market forecast analysis for FECD in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in FECD.

Drug Summary:

K-321 (Ripasudil), being developed by Kowa Pharmaceuticals, is a rho-kinase inhibitor that lowers intraocular pressure (IOP) by increasing conventional aqueous outflow. Rho-associated protein kinase (ROCK) is a protein that regulates the shape and movement of cells in several tissues, including the eye.

ROCK inhibitors lower IOP by depolymerizing intracellular actin in the conventional outflow tissues: the Trabecular Meshwork (TM) and Schlemm's canal (SC). Furthermore, ROCK inhibitors suppress extracellular matrix production by TM cells, representing a potential alternative to lowering IOP.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the K-321 description, mechanism of action, dosage and administration, research and development activities in Fuchs Endothelial Corneal Dystrophy (FECD).
• Elaborated details on K-321 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the K-321 research and development activities in FECD across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around K-321.
• The report contains forecasted sales of K-321 for FECD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for FECD.
• The report also features the SWOT analysis with analyst views for K-321 in FECD.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

K-321 Analytical Perspective by DelveInsight

• In-depth K-321 Market Assessment

This report provides a detailed market assessment of K-321 for Fuchs Endothelial Corneal Dystrophy (FECD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• K-321 Clinical Assessment

The report provides the clinical trials information of K-321 for FECD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Fuchs Endothelial Corneal Dystrophy (FECD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence K-321 dominance.
• Other emerging products for FECD are expected to give tough market competition to K-321 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of K-321 in FECD.
• Our in-depth analysis of the forecasted sales data of K-321 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the K-321 in FECD.

Key Questions

• What is the product type, route of administration and mechanism of action of K-321?
• What is the clinical trial status of the study related to K-321 in Fuchs Endothelial Corneal Dystrophy (FECD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the K-321 development?
• What are the key designations that have been granted to K-321 for FECD?
• What is the forecasted market scenario of K-321 for FECD?
• What are the forecasted sales of K-321 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to K-321 for FECD?
• Which are the late-stage emerging therapies under development for the treatment of FECD?

Table of Contents

1. Report Introduction

2. K-321 Overview in FECD

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. K-321 Market Assessment

• 5.1. Market Outlook of K-321 in FECD
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of K-321 in the 7MM for FECD
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of K-321 in the United States for FECD
  • 5.3.2. Market Size of K-321 in Germany for FECD
  • 5.3.3. Market Size of K-321 in France for FECD
  • 5.3.4. Market Size of K-321 in Italy for FECD
  • 5.3.5. Market Size of K-321 in Spain for FECD
  • 5.3.6. Market Size of K-321 in the United Kingdom for FECD
  • 5.3.7. Market Size of K-321 in Japan for FECD

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options